1908444-28-9

Usage

Uses

Used in Pharmaceutical Industry:
Obeticholic Acid impurity is used as a pharmaceutical agent for the treatment of liver-related diseases. Its activation of the farnesoid X nuclear receptor helps in reducing liver fat and fibrosis in animal models of fatty liver disease, making it a promising candidate for the development of therapeutic interventions.
Used in Research and Development:
Obeticholic Acid impurity serves as an essential compound in the research and development of novel drugs targeting liver diseases. Its unique properties and mechanism of action provide valuable insights into the development of new therapeutic strategies and potential drug candidates.
Used in Drug Delivery Systems:
Similar to Gallotannin, Obeticholic Acid impurity can be incorporated into drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. This application can potentially improve the efficacy of treatments for liver diseases and other related conditions.

Relevant academic research and scientific papers

Preparation method of obeticholic acid impurities

The invention discloses a preparation method of obeticholic acid impurities, relates to a synthesis method of five impurities of obeticholic acid, and has important significance for synthesizing high-quality obeticholic acid. (E)-3 [beta]-hydroxy-6-ethylene-7-keto-5[ beta]-cholestane-24-acid (D), 3 [alpha], 7 [alpha]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (F), 3 [alpha], 7 [beta]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (G), 3 [alpha]-(3 [alpha], 7 [alpha]-dihydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acyloxy)-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (I) and 3-keto-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (L) are mainly researched.

Obeticholic acid dimer preparation method

The present invention relates to an obeticholic acid dimer preparation method, which comprises: protecting the carboxyl group and the hydroxyl group of obeticholic acid to obtain 3[alpha],7[alpha]-dihydroxy-6[alpha]-ethyl-5[beta]-cholanic acid benzyl ester (VI) and 3[alpha],7[alpha]-bis(4-methoxytriphenylmethyl)-6[alpha]-ethyl-5[beta]-cholanic acid (IV), carrying out esterification on the compounds IV and VI under an alkali condition, and sequentially removing the protection groups of the carboxyl group and the hydroxyl group to obtain the obeticholic acid dimer. According to the present invention, the prepared obeticholic acid dimer has the high purity, and can be well used for the obeticholic acid impurity research without further purification.

A [...] dimer impurity and its preparation method (by machine translation)

The invention relates to a [...] dimer impurity and its preparation method, the preparation method comprises the following sequence of steps carried out: S1: [...] dimer impurity crude compound preparation; S2: [...] dimer impurity crude compound column chromatography separation and purification. The purpose of this invention is that the preparation [...] synthesis and degradation in the process of dimer impurity, can better control the quality of the [...], improve the drug safety. (by machine translation)